Article
A randomized study of extended treatment with peginterferon alpha-2b plus ribavirin based on time to HCV RNA negative-status in patients with genotype 1b chronic hepatitis C.
The American journal of gastroenterology - 1 Jan 2009
Ide Tatsuya, Hino Teruko, Ogata Kei, Miyajima Ichiro, Kuwahara Reiichiro, Kuhara Koichiro, Sata Michio
Abstract excerpt
OBJECTIVES: The treatment of patients with hepatitis C virus (HCV) genotype 1 with peginterferon plus ribavirin treatment for more than 48 weeks demonstrated high sustained virological response (SVR) rates. Although many studies extended the duration of therapy from 48 weeks to 72 weeks, the optimal duration has not yet been determined. METHODS: A total of 113 genotype 1b patients with high viral load were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.